Agreement enables AbbVie to leverage ConcertAI and Caris' extensive clinical and genomic databases, coupled with Artificial Intelligence and Machine Learning (AI/ML)-derived insights to accelerate drug discovery, clinical development and precision medicine efforts in oncology

该协议使AbbVie能够利用ConcertAI和Caris广泛的临床和基因组数据库，以及人工智能和机器学习（AI/ML）衍生的见解，以加速肿瘤学的药物发现，临床开发和精准医学工作

CAMBRIDGE, Ma. and IRVING, Texas, Jan. 9, 2024 /PRNewswire/ -- ConcertAI and Caris Life Sciences (Caris) announced a multi-year partnership to support AbbVie's precision medicine-driven research and development efforts, and clinical trial optimization in oncology.

马萨诸塞州剑桥市和德克萨斯州欧文市，2024年1月9日/PRNewswire/-ConcertAI和Caris Life Sciences（Caris）宣布建立多年合作伙伴关系，以支持AbbVie的精准医学驱动的研究和开发工作，以及肿瘤学的临床试验优化。

The agreement will allow AbbVie to leverage Caris' expansive real-world, multi-modal database in oncology and ConcertAI's collection of research-grade clinical data across a wide range of cancers, to guide the development of novel therapies for patients most likely to benefit. The agreement will also allow AbbVie to utilize ConcertAI and Caris' clinical network and laboratory capabilities combined with AI/ ML learning to optimize oncology clinical trials and patient enrollment..

该协议将使AbbVie能够利用Caris在肿瘤学领域的扩展性现实世界多模式数据库和ConcertAI在各种癌症中收集的研究级临床数据，为最有可能受益的患者开发新疗法。该协议还将允许AbbVie利用ConcertAI和Caris的临床网络和实验室能力，结合AI/ML学习，优化肿瘤学临床试验和患者登记。。

'We are continuing to expand our drug discovery and development efforts in oncology, with the ultimate goal to deliver transformative treatments to cancer patients,' said Tom Hudson, SVP, Chief Scientific Officer, Global Research at AbbVie. 'This agreement marks a key step in that direction, as it represents a union of cutting-edge technology and pioneering science, leveraging the power of big data, artificial intelligence and machine learning to propel our efforts in the fight against cancer.'.

AbbVie全球研究首席科学官高级副总裁汤姆·哈德森（TomHudson）说：“我们正在继续扩大我们在肿瘤学领域的药物发现和开发工作，最终目标是为癌症患者提供变革性治疗。”这项协议标志着朝着这个方向迈出了关键的一步，因为它代表了尖端技术和开创性科学的结合，利用大数据、人工智能和机器学习的力量来推动我们对抗癌症的努力。”。

'This partnership furthers our goals of enabling causal biological inferences, where multi-modal data can be integrated with AI/ML-based approaches in drug discovery, translation and development, to accelerate oncology pipelines, and allow our biopharma partners to discover and deliver better medicines faster,' said Jeff Elton, Ph.D., CEO of ConcertAI..

ConcertAI首席执行官杰夫·埃尔顿（Jeff Elton）博士说：“这种合作关系进一步推动了我们实现因果生物学推断的目标，在这种推断中，多模式数据可以与基于AI/ML的药物发现，翻译和开发方法相结合，以加速肿瘤学管道，并使我们的生物制药合作伙伴能够更快地发现和提供更好的药物。”。。

'We are thrilled to work with AbbVie, a leader in driving innovation in drug development, to support their work in oncology,' said Dr. George W. Sledge, Jr., Chief Medical Officer of Caris. 'This work may help identify novel targets and mechanisms, and key levers to drive clinical trial excellence to support AbbVie's oncology portfolio.' .

Caris首席医疗官乔治·W·斯莱奇（GeorgeW.Sledge）博士说，我们很高兴与推动药物开发创新的领导者艾伯维（AbbVie）合作，支持他们在肿瘤学方面的工作这项工作可能有助于确定新的目标和机制，以及推动临床试验卓越的关键杠杆，以支持AbbVie的肿瘤学组合。”。

About ConcertAI:

关于ConcertAI：

ConcertAI is the leader in Real-World Evidence (RWE) and Generative AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies.  Serving over 1,900 clinical sites and 45 biomedical innovators ConcertAI companies and solutions are Best in KLAS and awarded the 2020, 2021, and 2022 KLAS recognition.

ConcertAI是生命科学和医疗保健领域的现实世界证据（RWE）和生成人工智能技术解决方案的领导者。我们的使命是与领先的生物医学创新者、医疗保健提供者和医学协会合作，通过领先的数据、人工智能技术和科学专业知识，加速患者的见识和成果。服务于1900多个临床站点和45个生物医学创新者协奏会公司和解决方案是KLAS中最好的，并获得2020年、2021年和2022年KLAS认可。

Headquartered in Cambridge, MA, ConcertAI has offices in Philadelphia, Frankfurt, Raleigh-Durham, and Tokyo.  For more information, visit us at www.concertai.com..

协奏会总部位于马萨诸塞州剑桥市，在费城、法兰克福、罗利达勒姆和东京设有办事处。欲了解更多信息，请访问www.concertai.com。。

About Caris Life Sciences

关于Caris Life Sciences

Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease.

Caris Life Sciences®（Caris）是领先的下一代AI TechBio公司和精准医学先驱，正在积极开发和提供创新解决方案，以利用分子科学和AI彻底改变医疗保健并改善人类状况。通过全面的分子谱分析（全外显子组和全转录组测序）以及先进的AI和机器学习算法的应用，Caris创建了分析和揭示疾病分子复杂性所需的大规模临床基因组数据库和计算能力。

This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland.

测序能力，大数据和人工智能技术的这种融合提供了一个无与伦比的平台，可以提供下一代精准医学工具，用于早期检测，诊断，监测，治疗选择和药物开发。Caris总部位于德克萨斯州欧文，在凤凰城、纽约、剑桥（MA）、日本东京和瑞士巴塞尔设有办事处。

Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com..

Caris或其分销商合作伙伴在美国、欧洲、亚洲和其他国际市场提供服务。要了解更多信息，请访问CarisLifeSciences.com。。

SOURCE ConcertAI

来源协奏曲